ライフサイエンスコーパス: monoamine oxidase

1 of the aromatic amino acid decarboxylase and monoamine oxidase.

2 yr430 is conserved in the homologous protein monoamine oxidase.

3 a semicarbazide-sensitive copper-containing monoamine oxidase.

4 pamine to DOPAC by the mitochondrial enzyme, monoamine oxidase.

5 ut influences of active efflux mechanisms or monoamine oxidases.

6 and tested for inhibitory activities against monoamine oxidases.

7 terases, N-methyl-D-aspartate receptors, and monoamine oxidases.

8 Human monoamine oxidase A (hMAOA) is considered to be unique a

9 near the covalent 8alpha-S-cysteinyl FAD in monoamine oxidase A (MAO A) and to test the suggestion t

10 Monoamine oxidase A (MAO A) degrades serotonin, norepine

11 The FAD binding site of human liver monoamine oxidase A (MAO A) has been investigated by mut

12 Mice deficient in monoamine oxidase A (MAO A) have elevated brain levels o

13 ly shown that the serotonin-degrading enzyme monoamine oxidase A (MAO A) is an important source of hy

14 Smokers have reduced levels of brain monoamine oxidase A (MAO A) leading to speculation that

15 A spontaneous monoamine oxidase A (MAO A) mutation (A863T) in exon 8 i

16 Monoamine oxidase A (MAO A) plays a central role in the

17 The interaction of recombinant human liver monoamine oxidase A (MAO A) with a series of phenethylam

18 The genetic deletion of monoamine oxidase A (MAO A), an enzyme that breaks down

19 Monoamine oxidase A (MAO A), encoded by the X chromosome

20 Converging evidence shows that monoamine oxidase A (MAO A), the key enzyme catalyzing s

21 However, it has been reported that monoamine oxidase A (MAO A, a major neurotransmitter-deg

22 by increased blood glucocorticoids and brain monoamine oxidase A (MAO A, which degrades monoamine neu

23 Monoamine oxidase A (MAO(A)) knockout mice have highly e

24 The use of selective inhibitors of monoamine oxidase A (MAO-A) and B (MAO-B) holds a therap

25 compared to linezolid but suffer from potent monoamine oxidase A (MAO-A) inhibition and low solubilit

26 Monoamine oxidase A (MAO-A) is a key enzyme in the catab

27 Monoamine oxidase A (MAO-A) is a key regulator of seroto

28 Monoamine oxidase A (MAO-A) is an important brain enzyme

29 Monoamine oxidase A (MAO-A) is an important enzyme on th

30 o counter the effects of the 40% increase in monoamine oxidase A (MAO-A) levels that occurs during PP

31 One such biological abnormality is elevated monoamine oxidase A (MAO-A) levels, which occurs in the

32 ylglycolaldehyde (DOPEGAL) is the neurotoxic monoamine oxidase A (MAO-A) metabolite of norepinephrine

33 ating transcription of the gene encoding the monoamine oxidase A (MAO-A) to reduce serotonin levels i

34 We found that monoamine oxidase A (MAO-A) was the most significantly u

35 zolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired

36 region contains, among others, the genes for monoamine oxidase A (MAOA) and B (MAOB), which are invol

37 We examined the impact of constitutive monoamine oxidase A (MAOA) deficiency in mice on nicotin

38 Mice lacking monoamine oxidase A (MAOA) display high levels of brain

39 A functional promoter polymorphism in the monoamine oxidase A (MAOA) gene has been implicated as a

40 examining allelic variation in the X-linked monoamine oxidase A (MAOA) gene, previously associated w

41 esonance imaging and genetic analysis of the monoamine oxidase A (MAOA) gene, we investigated how str

42 olymorphisms in dopamine receptor (DRD4) and monoamine oxidase A (MAOA) genes showed significant asso

43 (5HT) and the monoamine-metabolizing enzyme monoamine oxidase A (MAOA) have been repeatedly implicat

44 We report that monoamine oxidase A (MAOA) is a clinically and functiona

45 Monoamine oxidase A (MAOA) is a mitochondrial enzyme tha

46 The rs1137070 polymorphism of monoamine oxidase A (MAOA) is associated with alcoholism

47 ohorts of Finnish prisoners, revealed that a monoamine oxidase A (MAOA) low-activity genotype (contri

48 Pharmacologic blockade of monoamine oxidase A (MAOA) or serotonin transporter (5-H

49 g growth differentiation factor-3 (GDF3) and monoamine oxidase A (MAOA) that is known to degrade nora

50 ing the neurotransmitter-metabolizing enzyme monoamine oxidase A (MAOA) was found to moderate the eff

51 6 member 2 (SLC6A2), an NE transporter, and monoamine oxidase A (MAOA), a degradation enzyme.

52 Monoamine oxidase A (MAOA), a mitochondria-bound enzyme,

53 cancer (PCa) exhibit increased expression of monoamine oxidase A (MAOA), a mitochondrial enzyme that

54 polymorphisms affecting transcription level: monoamine oxidase A (MAOA), neuropeptide Y (NPY), endoth

55 Polymorphisms in the monoamine oxidase A (MAOA-LPR) and serotonin receptor 2A

56 rine secretion; P < 0.01), with no effect on monoamine oxidase A (serotonin catabolism), serotonin re

57 ents and four Sp1-binding sites in the human monoamine oxidase A 2-kb promoter.

58 Low monoamine oxidase A activity increased risk for conduct

59 NIRKO mice also exhibit increased levels of monoamine oxidase A and B (MAO A and B) leading to incre

60 In a screening for potential monoamine oxidase A and B inhibition ciproxifan showed e

61 ted high selectivity (>160x) against related monoamine oxidase A and B.

62 The degree of inhibition of monoamine oxidase A by R1 correlated with the level of R

63 ors, the sequences of three Sp1 sites in the monoamine oxidase A core promoter were used in the yeast

64 ryptophan hydroxylase 1 and a suppression of monoamine oxidase A expression (enzymes responsible for

65 gnificant association between high levels of monoamine oxidase A expression and poorly differentiated

66 e shown that the Sp1 family is important for monoamine oxidase A expression.

67 Monoamine oxidase A gene (MAOA) has earned the nickname

68 his study shows that glucocorticoid enhances monoamine oxidase A gene expression by 1) regulation of

69 Studies on the regulation of monoamine oxidase A gene expression have shown that the

70 s that R1 is a novel repressor that inhibits monoamine oxidase A gene expression.

71 hydroxyphenylglycolaldehyde (DOPEGAL) is the monoamine oxidase A metabolite of norepinephrine (NE) an

72 re was a main effect of adversity but not of monoamine oxidase A on risk for conduct disorder.

73 tistically significant effects on binding to monoamine oxidase A or to the norepinephrine transporter

74 R1 was also found to repress monoamine oxidase A promoter activity within a natural c

75 toma cell line, SK-N-BE (2)-C, inhibited the monoamine oxidase A promoter and enzymatic activity.

76 R1 also bound directly to the natural monoamine oxidase A promoter in vivo as shown by chromat

77 A deficiency in monoamine oxidase A results in aggressive behavior in bo

78 d binding to the norepinephrine transporter, monoamine oxidase A, and alpha2-adrenoceptors were measu

79 ith clorgyline, an irreversible inhibitor of monoamine oxidase A, restored hippocampal noradrenaline

80 affinity to recombinant rat cerebral cortex monoamine oxidases A (MAO A) and B (MAO B) determined.

81 tion and activity of recombinant human liver monoamine oxidases A and B (MAO A and B).

82 dent amine oxidizing enzymes including human monoamine oxidases A and B (MAO A and MAO B) show aromat

83 The monoamine oxidases A and B (MAO-A and -B) genes, which a

84 Monoamine oxidases A and B (MAO-A and MAO-B) are enzymes

85 rs with notable selectivity toward SSAO over monoamine oxidases A and B (MAO-A and MAO-B).

86 cture (which also has inhibitory activity at monoamine oxidases A and B and at the serotonin and nore

87 ty towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H3 recep

88 Cloning of MAO (monoamine oxidase) A and B has demonstrated unequivocall

89 ompanied by an increase in the expression of monoamine oxidase-A (MAO-A) and MAO-B in the lateral OFC

90 Monoamine oxidase-A (MAO-A) is a treatment target in neu

91 Monoamine oxidase-A (MAO-A), a key brain enzyme which me

92 cluding catechol-O-methyltransferase (COMT), monoamine oxidase-A (MAO-A), vesicular monoamine transpo

93 study examined how the mitochondrial enzyme monoamine oxidase-A (MAO-A), which produces hydrogen per

94 eas was similarly modulated by inhibition of monoamine oxidase-A and was reduced in animals with indu

95 tor), SERT RNA-interference, and iproniazid (monoamine oxidase-A inhibitor), blocked 5-HT-induced S10

96 the current study, we used a genetic model (monoamine oxidase-A knockout mouse) in which brain 5-HT

97 3,4-Dihydroxyphenylglycolaldehyde is the monoamine oxidase-A metabolite of two catecholamine neur

98 luded those involved in cellular metabolism: monoamine oxidase-A, mitochondrial-A synthase complex, a

99 -serotonin and increased after inhibition of monoamine oxidase-A, the main enzyme responsible for ser

100 Recent observations of lower monoamine oxidase activity (which may play a role in cen

101 Ebselen had no effect on the monoamine oxidase activity and did not protect against M

102 dopamine transporter expression, and inhibit monoamine oxidase activity while increasing tyrosine hyd

103 K1/2 nuclear translocation depended on SERT, monoamine oxidase activity, and reactive oxygen species.

104 form (sVAP-1) accounts for most circulating monoamine oxidase activity, has insulin-like effects, an

105 o competitive MPP(+)-dependent inhibition of monoamine oxidase activity.

106 through stepwise transformation catalyzed by monoamine oxidase, aldehyde dehydrogenase and aldehyde r

107 eneration: (a) MPTP oxidation to MPP(+) by a monoamine oxidase and (b) NADH dehydrogenase inhibition

108 In addition, they showed lower activities of monoamine oxidase and dopamine beta hydroxylase in the h

109 en), and neurotransmitter enzyme inhibition (monoamine oxidase and glutamic acid decarboxylase).

110 flavoenzymes that oxidize amines, including monoamine oxidase and trimethylamine dehydrogenase.

111 urons greatly increases the transcription of monoamine oxidases and oxidative stress, significantly r

112 cascade consisting of the ATHase, the GDH, a monoamine oxidase, and a catalase leads to the productio

113 d by the transaminase is not affected by the monoamine oxidase, and highlights the potential of this

114 As the H3R and monoamine oxidases are all capable of affecting neurotra

115 ine oxidase, copper containing 3), a surface monoamine oxidase, as a new marker of myofibroblasts by

116 Monoamine oxidase B (MAO B) catalyzes the oxidative deam

117 The monotopic membrane protein monoamine oxidase B (MAO B) is an important drug target

118 al reversible inhibitors selective for human monoamine oxidase B (MAO B) that do not inhibit MAO A ha

119 (AD), i.e., acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), a series of multitarget lig

120 A set of drugs was further studied in monoamine oxidase B (MAO-B) and cyclooxygenase-1 (COX-1)

121 mine and compare how two monotopic proteins, monoamine oxidase B (MAO-B) and cyclooxygenase-2 (COX-2)

122 Age-related increases in brain monoamine oxidase B (MAO-B) and its ability to produce r

123 l) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10

124 enosine receptors (A2AARs) and inhibition of monoamine oxidase B (MAO-B) in the brain are considered

125 mined the effects of GM1 ganglioside and the monoamine oxidase B (MAO-B) inhibitor L-deprenyl, alone

126 llular model of Parkinson's disease in which monoamine oxidase B (MAO-B) is overexpressed and which e

127 evious finding that smokers have lower brain monoamine oxidase B (MAO-B) levels than comparison nonsm

128 e, competitive, and reversible inhibitors of monoamine oxidase B (MAO-B).

129 or (NMDAR), acetylcholinesterase (AChE), and monoamine oxidase B (MAO-B).

130 diographically in conscious mice without the monoamine oxidase B (MAOB) gene (KO, n=11) and the corre

131 was found to suppress the gene expression of monoamine oxidase B (MAOB) in the brain of wild-type but

132 brane domains from the mitochondrial protein monoamine oxidase B (MaoB) or the endoplasmic reticulum

133 tural comparisons with human metabolites and monoamine oxidase B (MAOB) was identified as the putativ

134 g agent, flecainide, which has no recognized monoamine oxidase B activity, and which has previously b

135 example of a biorelevant synthetic model for monoamine oxidase B activity.

136 amine N-methyl transferase) and disposition (monoamine oxidase B and catechol-O-methyl transferase) o

137 We performed a genomewide scan of monoamine oxidase B for the Collaborative Study on the G

138 trate for the flavin-dependent mitochondrial monoamine oxidase B from bovine liver.

139 a targeting enzyme to disrupt the endogenous monoamine oxidase B gene in human cells.

140 onoamine oxidases with slight preference for monoamine oxidase B in both species.

141 SKF-38393 had no effects either on total or monoamine oxidase B in the striatum.

142 We report the effects of the addition of a monoamine oxidase B inhibitor, rasagiline, to antidepres

143 est placebo-controlled clinical trial of the monoamine oxidase B inhibitor, rasagiline, we examined h

144 2D6 inhibitor, quinidine, and also partly by monoamine oxidase B inhibitors deprenyl and pargyline.

145 Monoamine oxidase B inhibitors result in a mild improvem

146 his, a number of highly potent and selective monoamine oxidase B inhibitors were identified.

147 dowed with potent, selective, and reversible monoamine oxidase B inhibitory activity is a clinically

148 Also, we demonstrate that monoamine oxidase B is an ERRalpha target gene whose exp

149 -deuterium-L-deprenyl ((11)C-DED) to measure monoamine oxidase B located in astrocytes.

150 rkinson's disease based on its inhibition of monoamine oxidase B, but the drug is also a potent state

151 Monoamine oxidase B, present in the mitochondrial outer

152 nction and these include redox-related genes monoamine oxidase B, ryanodine receptor 2, and glutathio

153 rmed with 1-PCPA and mammalian mitochondrial monoamine oxidase B.

154 Monoamine oxidase-B (MAO-B) is a key enzyme in the catab

155 MPTP is converted by monoamine oxidase-B (MAO-B) to its neurotoxic metabolite

156 oduce the inhibitory gliotransmitter GABA by monoamine oxidase-B (Maob) and abnormally release GABA t

157 ned most (50-60%) of marker enzyme activity, monoamine oxidase-B and porin proteins, but only about 2

158 Accordingly, monoamine oxidase blockers pargyline and l-deprenyl had

159 hat renalase is the third monoamine oxidase (monoamine oxidase C) that oxidizes circulating catechola

160 Monoamine oxidase catalyzes the oxidative deamination of

161 tabolism of dopamine involves three enzymes: monoamine oxidase, catechol O-methyltransferase, and sul

162 Monoamine oxidase converts dopamine to 3,4-dihydroxyphen

163 f the metabolizing enzymes of citalopram and monoamine oxidases did not modify the permeation of cita

164 nhibition of either serotonin reuptake or of monoamine oxidase, dopamine neurons accumulate serotonin

165 mine (2, MBA236) as a new cholinesterase and monoamine oxidase dual inhibitor.

166 that it has the same fold as members of the monoamine oxidase family of flavoproteins, with the grea

167 Structurally, PAO is a member of the monoamine oxidase family of flavoproteins.

168 e enzyme are conserved in all members of the monoamine oxidase family, Lys365 and Trp466.

169 ved active site residue found throughout the monoamine oxidase family.

170 Monoamine oxidase from Aspergillus niger (MAO-N) is a fl

171 shares 81.0% similarity with the 763-residue monoamine oxidase from human placenta (HPAO) (the N-term

172 ndividuals or for those undergoing classical monoamine oxidase inhibiting (MAOI) drug therapy.

173 Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent

174 of smoking behavior and the contribution of monoamine oxidase inhibition to compulsive nicotine-seek

175 tudy the effects of fluorine substitution on monoamine oxidase inhibition.

176 ibitor (SSRI) fluoxetine (10 mg/kg), and the monoamine oxidase inhibitor (MAOI) phenelzine (10 mg/kg)

177 Hamsters were treated chronically with the monoamine oxidase inhibitor (MAOI), clorgyline, and then

178 uoxetine) or norepinephrine (desipramine), a monoamine oxidase inhibitor (tranylcypromine), and elect

179 ective reuptake inhibitor (fluoxetine), or a monoamine oxidase inhibitor (tranylcypromine).

180 side effects commonly seen with traditional monoamine oxidase inhibitor antidepressants were not obs

181 dose response experiments with tricyclic or monoamine oxidase inhibitor antidepressants.

182 ive to standard acute-phase treatment with a monoamine oxidase inhibitor for outpatients with major d

183 While tricyclic and monoamine oxidase inhibitor medications were associated

184 e inhibitors desipramine and reboxetine, the monoamine oxidase inhibitor pargyline, and the atypical

185 Our lab has found opposing effects of the monoamine oxidase inhibitor phenelzine and the tricyclic

186 group therapy (CBGT) and treatment with the monoamine oxidase inhibitor phenelzine sulfate for socia

187 reuptake inhibitor desipramine (DMI), or the monoamine oxidase inhibitor phenelzine.

188 n has also been introduced in a study of the monoamine oxidase inhibitor rasagiline, demonstrating a

189 selective serotonin reuptake inhibitor or a monoamine oxidase inhibitor rather than a tricyclic anti

190 As part of the clinical trials of the monoamine oxidase inhibitor selegiline for treating coca

191 n by RNAi in human erythroid cells or by the monoamine oxidase inhibitor tranylcypromine in human ery

192 ibitor) and tranylcypromine (10 mg/kg, i.p., monoamine oxidase inhibitor) with each drug being inject

193 st and present clinical trials of tricyclic, monoamine oxidase inhibitor, and selective serotonin reu

194 However, neither pargyline, a specific monoamine oxidase inhibitor, nor semicarbazide, a specif

195 Combined with pargyline, a monoamine oxidase inhibitor, reserpine increased catecho

196 sion or of cognitive therapy compared with a monoamine oxidase inhibitor.

197 covery of a new class of compounds acting as monoamine oxidase inhibitors (MAO-Is) and bearing a 6'-s

198 Because monoamine oxidase inhibitors (MAOI) are often more effec

199 We previously assessed monoamine oxidase inhibitors (MAOIs) for their ability t

200 n of LSD1 or inhibition of its activity with monoamine oxidase inhibitors (MAOIs) results in the accu

201 been treated with tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), fluoxetine, or pla

202 ects on outcomes compared with waitlist were monoamine oxidase inhibitors (SMD -1.01, 95% credible in

203 Although monoamine oxidase inhibitors are effective in treating a

204 In this study, administration of the monoamine oxidase inhibitors clorgyline and deprenyl res

205 f smoking behavior in humans and presence of monoamine oxidase inhibitors in tobacco smoke, we hypoth

206 cal depression are more likely to respond to monoamine oxidase inhibitors than to tricyclic antidepre

207 idepressants (eg, tricyclic antidepressants, monoamine oxidase inhibitors) were excluded.

208 reated with beta-blockers, ACE inhibitors or monoamine oxidase inhibitors, in children under 5 years

209 studies of the neuroprotective properties of monoamine oxidase inhibitors, we found that phenelzine p

210 es and aromatic amino acid decarboxylase and monoamine oxidase inhibitors.

211 at such patients responded preferentially to monoamine oxidase inhibitors.

212 In prior studies, it has been shown that monoamine oxidase inhibitory scaffolds such as propargyl

213 etic modeling suggests a lower potential for monoamine oxidase interaction, and animal and human subj

214 Monoamine oxidase is an outer mitochondrial membrane pro

215 The monoamine oxidase isoenzymes (MAOs) A and B play importa

216 es was synthesized and screened toward human monoamine oxidase isoforms (hMAO-A and hMAO-B).

217 hibitory properties tested for the two human monoamine oxidase isoforms (hMAOA and hMAOB).

218 The flavin-dependent monoamine oxidase LSD1 (lysine-specific demethylase 1, a

219 M1 family is homologous to the mitochondrial monoamine oxidases MAO-A/B and produces hydrogen peroxid

220 cids on the activity and solubility of human monoamine oxidase (MAO B), 10 sequential mutants were ma

221 its IC(50) against the functionally related monoamine oxidase (MAO) -A and MAO-B is >10 microM.

222 Monoamine oxidase (MAO) A and B catalyze the oxidative d

223 signed, synthesized, and evaluated for their monoamine oxidase (MAO) A and B inhibiting effect.

224 SY5Y markedly reduced the activities of both monoamine oxidase (MAO) A and B.

225 report for the first time that VPA activates monoamine oxidase (MAO) A catalytic activity, mRNA level

226 as recently suggested that partially reduced monoamine oxidase (MAO) A contains an equilibrium mixtur

227 studies have established that abrogation of monoamine oxidase (MAO) A expression leads to a neuroche

228 Monoamine oxidase (MAO) A is a key enzyme for the degrad

229 uran was a potent and selective inhibitor of monoamine oxidase (MAO) A.

230 ly demonstrated direct evidence of increased monoamine oxidase (MAO) activity in the brain of a simia

231 EN, particularly its sensitivity to neuronal monoamine oxidase (MAO) activity, kinetic studies in an

232 direct effects of CSC and A(2A) receptors on monoamine oxidase (MAO) activity, we found that CSC pote

233 ts structural analogues on the activities of monoamine oxidase (MAO) and ALDH-2, the key enzymes invo

234 tonin 5-HT1A receptor antagonist) as well as monoamine oxidase (MAO) and functional binding assays we

235 uate its potential to visualize and quantify monoamine oxidase (MAO) B activity in vivo.

236 Monoamine oxidase (MAO) B deaminates a number of biogeni

237 The human monoamine oxidase (MAO) B plays a major role in the degr

238 e amides also exhibited less potency against monoamine oxidase (MAO) enzymes and thus possess less po

239 Monoamine oxidase (MAO) expression was increased in cell

240 ough receptors R3 and R4 and the activity of monoamine oxidase (MAO) in the establishment of correct

241 late central monoamine levels partly through monoamine oxidase (MAO) inhibition.

242 Wistar rats and on rats pretreated with the monoamine oxidase (MAO) inhibitor clorgyline.

243 endogenous imidazoline ligand agmatine, the monoamine oxidase (MAO) inhibitor harmane, the alpha(2)-

244 ble dopamine-beta-monooxygenase (DbetaM) and monoamine oxidase (MAO) inhibitors.

245 Monoamine oxidase (MAO) is a key enzyme responsible for

246 Monoamine oxidase (MAO) is responsible for the oxidation

247 at cigarette smoke constituents that inhibit monoamine oxidase (MAO) may increase the reinforcing val

248 be an inactivator of the fungal flavoenzyme monoamine oxidase (MAO) N.

249 The flavoenzyme monoamine oxidase (MAO) regulates mammalian behavioral p

250 Monoamine oxidase (MAO) regulates neurotransmitter conce

251 wo-step homogeneous bioluminescent assay for monoamine oxidase (MAO) that is simple, sensitive, and a

252 An interesting flavoprotein-type monoamine oxidase (MAO) was recently isolated from Asper

253 ling in striatum: mitochondrial respiration, monoamine oxidase (MAO), and NADPH oxidase (Nox).

254 lamine), which is a monoamine metabolized by monoamine oxidase (MAO), exists widely in plants, animal

255 coding serotonin and dopamine receptors, and monoamine oxidase (MAO)-A in brains of sub-adult pigs we

256 Further, we have identified the monoamine oxidase (MAO)-aldehyde dehydrogenase (ALDH-2)

257 ine oxidases including polyamine oxidase and monoamine oxidase (MAO).

258 nd vasoactive dietary amines is oxidation by monoamine oxidase (MAO).

259 PHEN is also a substrate for monoamine oxidase (MAO).

260 kidney diamine oxidase (pkDAO) or rat liver monoamine oxidase (MAO-B).

261 ein, a novel one-pot omega-transaminase (TA)/monoamine oxidase (MAO-N) cascade process for the synthe

262 Monoamine oxidases (MAO) A and B are approximately 60-kD

263 e inactivation of purified human recombinant monoamine oxidases (MAO) A and B by rasagiline [N-propar

264 Monoamine oxidases (MAO) A and B catalyze the oxidative

265 Monoamine oxidases (MAO) A and B deaminate a number of b

266 valuation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose

267 gnificant sequence similarities to mammalian monoamine oxidases (MAO) A and B, as well as to bacteria

268 idative stress by limiting the expression of monoamine oxidases (MAO)--mitochondrial enzymes responsi

269 of the active site cavities in human and rat monoamine oxidases (MAOA and MAOB) have been studied in

270 Drug interaction between inhibitors of monoamine oxidase (MAOIs) and selective serotonin (5-hyd

271 arins were designed, prepared, and tested as monoamine oxidases (MAOs) and acetyl- and butyryl-cholin

272 endent amine oxidases, certain inhibitors of monoamine oxidases (MAOs), including the clinically used

273 carbonyl reductases (CREDs), hydrolases and monoamine oxidases (MAOs), providing a comprehensive ove

274 ds are capable of inducing the activities of monoamine oxidases (MAOs), which degrade monoamine neuro

275 d access to nicotine, and that inhibition of monoamine oxidase may contribute to the escalation of sm

276 The suggestion that polyamine oxidase and monoamine oxidase may have structural homology appears t

277 Previous studies have implicated the monoamine oxidase metabolite of DA, 3,4-dihydroxphenylac

278 ethyl transferase (COMT) and two isoforms of monoamine oxidase--modulated degree of belief learning a

279 n widely reported that renalase is the third monoamine oxidase (monoamine oxidase C) that oxidizes ci

280 inactivated with three known inactivators of monoamine oxidase, namely, phenylhydrazine, N-cyclopropy

281 g sites for [(18)F]AV-1451, such as neuronal monoamine oxidase or neuromelanin.

282 siHLAO1 and psiHLAO2, of a copper-containing monoamine oxidase pseudogene have been isolated from a h

283 Metabolism of dopamine by monoamine oxidase results in the formation of hydrogen p

284 h extended (>30 ns) atomistic simulations of monoamine oxidase, revealing good agreement between the

285 ble and specific for LSD1 as compared to the monoamine oxidases shows minimal inhibition of CYPs and

286 3,4-dihydroxyphenylacetaldehyde (DOPAL) via monoamine oxidase significantly increases its toxicity.

287 ism of amine oxidation by this member of the monoamine oxidase structural family.

288 Polymorphisms in monoamine oxidase (T1460CA) were associated with increas

289 re, we demonstrate that AMX-2 is the primary monoamine oxidase that metabolizes 5-HT in C. elegans, a

290 d allele-specific expression of the X-linked monoamine oxidase type A (MAOA) gene and the expression

291 e carbidopa/levodopa, dopamine agonists, and monoamine oxidase type B (MAO-B) inhibitors.

292 this review, we focus on recent studies with monoamine oxidase type B inhibitors (selegiline and rasa

293 ptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine

294 pyridine (MPTP) is dependent upon the MAO-B (monoamine oxidase type B)-catalyzed production of 1-meth

295 e (24-48 h), and after chronic inhibition of monoamine oxidase using phenelzine sulfate.

296 evelopment and application of a "toolbox" of monoamine oxidase variants from Aspergillus niger (MAO-N

297 Rat liver mitochondrial monoamine oxidase was also inactivated by 4, as expected

298 n DOPAL levels were blocked by inhibition of monoamine oxidase with clorgyline indicating that accumu

299 Moreover, inhibition of monoamine oxidase with daily administration of phenelzin

300 omolar concentration range for human and rat monoamine oxidases with slight preference for monoamine